A phase 1 single and multiple ascending dose study of orforglipron in Japanese participants with type 2 diabetes
In Japanese participants, safety, pharmacokinetic, and pharmacodynamic results were similar to those of previous orforglipron studies. The safety and tolerability of orforglipron were also consistent with those of other glucagon-like peptide-1 receptor agonists. Orforglipron is a potential new treatment option for Japanese patients with type 2 diabetes.
Authors
- Tetsuaki Hirase (ORCID: https://orcid.org/0000-0003-1691-8003)
- Chizuko Nakamura (ORCID: https://orcid.org/0000-0003-2346-4361)
- Kenji Ohwaki (ORCID: https://orcid.org/0000-0002-2842-8231)
- Risa Nasu (ORCID: https://orcid.org/0000-0002-5258-8593)
- Kazumasa Takenouchi
Institutions
- Yokohama Minami Kyosai Hospital (JP)
- Eli Lilly (Japan) (JP)
Publication Details
- Journal
- Journal of Diabetes Investigation
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1111/jdi.70157
- Citations
- 1
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.29
Funders
- Eli Lilly and Company
- Eli Lilly Japan